SEC Comment Letter 0000000000-23-001283 to Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc.
Date: Feb. 7, 2023 · CIK: 0001831363 · Accession: 0000000000-23-001283
AI Filing Summary & Sentiment
File numbers found in text: 333-269508
Letter
United States securities and exchange commission logo February 7, 2023 Senthil Sundaram Chief Executive Officer Terns Pharmaceuticals, Inc. 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404 Re:Terns Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 1, 2023 File No. 333-269508 Dear Senthil Sundaram: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Johnson, Esq.
Show Raw Text
United States securities and exchange commission logo
February 7, 2023
Senthil Sundaram
Chief Executive Officer
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Blvd., Suite 100
Foster City, California 94404
Re:Terns Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed February 1, 2023
File No. 333-269508
Dear Senthil Sundaram:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian Johnson, Esq.